Literature DB >> 11995925

Induction of p16INK4a transcription and of cellular senescence by aclacinomycin-derivatives and cardiac glycosides.

Kiyoshi Egawa1, Yosuke Kurihara, Tatsuya Ito, Masahiko Matsumoto, Kiyoshi Nose.   

Abstract

Stable transformants of Saos-2 cells that contain the luciferase reporter gene under the control of the human p16INK4a transcriptional regulatory region were established, and were used to identify growth-inhibiting substances from culture broths of actinomycetes and extracts of plants. Among the active substances so far identified were an aclacinomycin-derivative, cenerubin B, and a cardiac glycoside, periplocin. These substances inhibited growth of normal human fibroblasts, and induced senescent phenotypes including a flattened morphology and increased acidic beta-galactosidase activity, although the activities of their derivatives to induce p16CDKN2 and beta-galactosidase did not coincided with each other. These results suggest that the reporter system using the p16CDKN2 transcriptional regulatory region is a useful means for screening growth inhibiting substances that are potential anti-tumor agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11995925     DOI: 10.1248/bpb.25.461

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Gene expression profiling of the proliferative effect of periplocin on mouse cardiac microvascular endothelial cells.

Authors:  Xiao-ying Wang; Xiu-mei Gao; Hong Liu; Han Zhang; Yang Liu; Min Jiang; Li-min Hu; Bo-li Zhang
Journal:  Chin J Integr Med       Date:  2010-02-04       Impact factor: 1.978

2.  P-glycoprotein- and organic anion-transporting polypeptide-mediated transport of periplocin may lead to drug-herb/drug-drug interactions.

Authors:  Sheng Liang; Fengchun Deng; Haiyan Xing; He Wen; Xiaoyan Shi; Orleans Nii Martey; Emmanuel Koomson; Xin He
Journal:  Drug Des Devel Ther       Date:  2014-05-09       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.